Design Therapeutics Inc (DSGN)

$7.37 +0.31 (4.39%)
Market Cap 419.83M
Revenue (ttm) 0.00
Net Income (ttm) -49.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 793,700
Avg Vol 278,100
Day's Range N/A - N/A
Shares Out 56.96M
Stochastic %K 68%
Beta 1.67
Analysts Sell
Price Target $8.33

Company Profile

Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progr...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 293 4900
Address:
6005 Hidden Valley Road, Suite 110, Carlsbad, United States
JarvisFlow
JarvisFlow Nov. 6 at 3:48 PM
RBC Capital updates rating for Design Therapeutics ( $DSGN ) to Sector Perform, target set at 5 → 6.
0 · Reply
d_risk
d_risk Nov. 5 at 9:31 PM
$DSGN - Design Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors DSGN’s risk factors now detail clinical trial setbacks including FDA clinical hold, side effect concerns, and reformulation of DT-216; expanded regulatory, IP, and competitive threats; new risks from patent law changes, licensing disputes, anti-corruption laws, anti-takeover provisions, and potential stock volatility from insider sales. #Biotechnology #StockVolatility #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/DSGN/10-Q/2025-11-05
0 · Reply
RunnerSignals
RunnerSignals Oct. 27 at 8:37 PM
$DQ $DSGN $SNAL $ARQQ $JANX finally shake off the sideways blues with big moves and strong volume
0 · Reply
Quantumup
Quantumup Oct. 6 at 1:56 PM
Citizens reiterated $LRMR at Market Outperform/$18 after hosting a call w/ the CEO of the Friedreich's Ataxia Research Alliance (FARA), Jennifer Farmer, on Friday, who said, 'The Patient Community Believes Nomlabofusp's Potential Benefits Outweigh Its Risks' $BIIB $LXEO $PTCT $DSGN Citizens JMP said:
0 · Reply
Quantumup
Quantumup Oct. 2 at 2:27 PM
Oppenheimer lowered $LRMR's price target to $21 from $26 to reflect the share count change following Larimar's recent capital raise; reiterated at Outperform. $BIIB $LXEO $PTCT $DSGN Oppenheimer said: Larimar reported positive results from the 50mg OLE cohort of nomla, supporting its use as the potentially first disease-modifying treatment in Friedreich's Ataxia (FA). Data were positive, demonstrating all OLE patients at 6-months reached skin frataxin levels over 50% of healthy volunteers along with improvements in clinical outcomes, though the seven cases of reported anaphylaxis in the OLE drew concern; while a potential concern, anaphylaxis is manageable. OPY sees LRMR's rebound from the previous day's selloff reflecting nomla's favorable benefit-risk profile in FA and still sees a buying opportunity ahead of the Q2 2026 BLA submission, followed by a potential early 2027 launch.
0 · Reply
Quantumup
Quantumup Sep. 16 at 7:23 PM
Guggenheim reiterated $LRMR at a Buy rating and a $26 PT after its FDA Expert (fmr. Director of the Division of Pharmacometrics at the FDA) Expressed High Conviction in $LRMR's Regulatory Case and Noted $BIIB's Qalsody as One of Several of His Case Points. [ $PTCT $LXEO $DSGN] Guggenheim said in its note:
1 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 8:47 AM
$DSGN Really good write-up that perfectly summarizes DSGN's present situation. So if you want to bring your DSGN knowledge up to date or just discover DSGN, this is required reading. https://beyondspx.com/quote/DSGN/design-therapeutics-unlocking-genomic-medicines-with-a-novel-small-molecule-approach-dsgn#analysis
0 · Reply
DARKP00L
DARKP00L Sep. 3 at 2:47 PM
$DSGN this stock is attracting a lot of interest. Be prepared for possible changes!
0 · Reply
QuizNose
QuizNose Aug. 28 at 9:13 PM
$DSGN New, Point72 filing: https://www.sec.gov/Archives/edgar/data/1807120/000090266425003881/xslSCHEDULE_13G_X01/primary_doc.xml
0 · Reply
Drugtrade
Drugtrade Aug. 26 at 3:48 PM
$DSGN 200 shares to start right here, fund accumulation may drive price up ahead of data catalyst. $25 target
0 · Reply
Latest News on DSGN
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:01 PM EST - 11 days ago

Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results

Design Therapeutics Appoints Justin Gover to Board of Directors

Sep 10, 2025, 4:01 PM EDT - 2 months ago

Design Therapeutics Appoints Justin Gover to Board of Directors

Design Therapeutics, Inc. (DSGN) Presents at Cantor Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 3:07 AM EDT - 2 months ago

Design Therapeutics, Inc. (DSGN) Presents at Cantor Global Healthcare Conference 2025 Transcript

Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

Aug 27, 2025, 8:00 AM EDT - 2 months ago

Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:01 PM EDT - 3 months ago

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

Jun 4, 2025, 7:00 AM EDT - 5 months ago

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 6 months ago

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

May 13, 2025, 8:00 AM EDT - 6 months ago

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

May 7, 2025, 4:01 PM EDT - 6 months ago

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

May 1, 2025, 8:00 AM EDT - 7 months ago

Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

Apr 21, 2025, 4:01 PM EDT - 7 months ago

Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

Apr 17, 2025, 8:00 AM EDT - 7 months ago

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 7:07 AM EDT - 9 months ago

Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results

Design Therapeutics to Participate in Leerink's Global Healthcare Conference

Mar 3, 2025, 8:00 AM EST - 9 months ago

Design Therapeutics to Participate in Leerink's Global Healthcare Conference

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

Nov 13, 2024, 8:00 AM EST - 1 year ago

Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

Nov 7, 2024, 4:01 PM EST - 1 year ago

Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

Aug 5, 2024, 8:00 AM EDT - 1 year ago

Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

May 8, 2024, 4:05 PM EDT - 1 year ago

Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

May 7, 2024, 6:30 AM EDT - 1 year ago

Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference

Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript

Mar 19, 2024, 8:44 PM EDT - 1 year ago

Design Therapeutics, Inc. (DSGN) Q4 2023 Earnings Call Transcript

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

Mar 19, 2024, 4:01 PM EDT - 1 year ago

Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

Mar 12, 2024, 6:30 AM EDT - 1 year ago

Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

Nov 13, 2023, 4:05 PM EST - 2 years ago

Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024

Design Therapeutics stock plunges on trial results for neuromuscular disease treatment

Aug 15, 2023, 8:17 AM EDT - 2 years ago

Design Therapeutics stock plunges on trial results for neuromuscular disease treatment

Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results

Aug 14, 2023, 4:05 PM EDT - 2 years ago

Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results

Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia

Aug 14, 2023, 4:01 PM EDT - 2 years ago

Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia

Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference

May 31, 2023, 6:30 AM EDT - 2 years ago

Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference

Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results

May 9, 2023, 4:05 PM EDT - 2 years ago

Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results

Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023

Apr 24, 2023, 6:30 AM EDT - 2 years ago

Design Therapeutics to Present Preclinical Data on its GeneTAC™ Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023

Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

Mar 14, 2023, 4:05 PM EDT - 2 years ago

Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results

Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

Feb 8, 2023, 6:30 AM EST - 3 years ago

Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

Dec 7, 2022, 4:01 PM EST - 3 years ago

Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress

Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

Nov 3, 2022, 4:05 PM EDT - 3 years ago

Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results

Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022

Oct 17, 2022, 4:05 PM EDT - 3 years ago

Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC™ Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022

Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

Sep 22, 2022, 6:30 AM EDT - 3 years ago

Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit

Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results

Aug 8, 2022, 4:05 PM EDT - 3 years ago

Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results

Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

Aug 3, 2022, 6:30 AM EDT - 3 years ago

Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference

Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference

Jun 1, 2022, 6:30 AM EDT - 3 years ago

Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference

Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results

May 9, 2022, 4:05 PM EDT - 3 years ago

Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results

Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia

Mar 30, 2022, 6:30 AM EDT - 3 years ago

Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC™ Molecule for the Treatment of Friedreich Ataxia

Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

Mar 10, 2022, 4:02 PM EST - 4 years ago

Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022

Mar 9, 2022, 6:30 AM EST - 4 years ago

Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC™ Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022

Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia

Feb 28, 2022, 4:05 PM EST - 4 years ago

Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia

Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Feb 10, 2022, 6:30 AM EST - 4 years ago

Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer

Feb 1, 2022, 4:05 PM EST - 4 years ago

Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer

Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

Jan 19, 2022, 12:51 PM EST - 4 years ago

Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results

Nov 9, 2021, 4:05 PM EST - 4 years ago

Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results

Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1

Sep 8, 2021, 6:30 AM EDT - 4 years ago

Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1

JarvisFlow
JarvisFlow Nov. 6 at 3:48 PM
RBC Capital updates rating for Design Therapeutics ( $DSGN ) to Sector Perform, target set at 5 → 6.
0 · Reply
d_risk
d_risk Nov. 5 at 9:31 PM
$DSGN - Design Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors DSGN’s risk factors now detail clinical trial setbacks including FDA clinical hold, side effect concerns, and reformulation of DT-216; expanded regulatory, IP, and competitive threats; new risks from patent law changes, licensing disputes, anti-corruption laws, anti-takeover provisions, and potential stock volatility from insider sales. #Biotechnology #StockVolatility #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/DSGN/10-Q/2025-11-05
0 · Reply
RunnerSignals
RunnerSignals Oct. 27 at 8:37 PM
$DQ $DSGN $SNAL $ARQQ $JANX finally shake off the sideways blues with big moves and strong volume
0 · Reply
Quantumup
Quantumup Oct. 6 at 1:56 PM
Citizens reiterated $LRMR at Market Outperform/$18 after hosting a call w/ the CEO of the Friedreich's Ataxia Research Alliance (FARA), Jennifer Farmer, on Friday, who said, 'The Patient Community Believes Nomlabofusp's Potential Benefits Outweigh Its Risks' $BIIB $LXEO $PTCT $DSGN Citizens JMP said:
0 · Reply
Quantumup
Quantumup Oct. 2 at 2:27 PM
Oppenheimer lowered $LRMR's price target to $21 from $26 to reflect the share count change following Larimar's recent capital raise; reiterated at Outperform. $BIIB $LXEO $PTCT $DSGN Oppenheimer said: Larimar reported positive results from the 50mg OLE cohort of nomla, supporting its use as the potentially first disease-modifying treatment in Friedreich's Ataxia (FA). Data were positive, demonstrating all OLE patients at 6-months reached skin frataxin levels over 50% of healthy volunteers along with improvements in clinical outcomes, though the seven cases of reported anaphylaxis in the OLE drew concern; while a potential concern, anaphylaxis is manageable. OPY sees LRMR's rebound from the previous day's selloff reflecting nomla's favorable benefit-risk profile in FA and still sees a buying opportunity ahead of the Q2 2026 BLA submission, followed by a potential early 2027 launch.
0 · Reply
Quantumup
Quantumup Sep. 16 at 7:23 PM
Guggenheim reiterated $LRMR at a Buy rating and a $26 PT after its FDA Expert (fmr. Director of the Division of Pharmacometrics at the FDA) Expressed High Conviction in $LRMR's Regulatory Case and Noted $BIIB's Qalsody as One of Several of His Case Points. [ $PTCT $LXEO $DSGN] Guggenheim said in its note:
1 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 8:47 AM
$DSGN Really good write-up that perfectly summarizes DSGN's present situation. So if you want to bring your DSGN knowledge up to date or just discover DSGN, this is required reading. https://beyondspx.com/quote/DSGN/design-therapeutics-unlocking-genomic-medicines-with-a-novel-small-molecule-approach-dsgn#analysis
0 · Reply
DARKP00L
DARKP00L Sep. 3 at 2:47 PM
$DSGN this stock is attracting a lot of interest. Be prepared for possible changes!
0 · Reply
QuizNose
QuizNose Aug. 28 at 9:13 PM
$DSGN New, Point72 filing: https://www.sec.gov/Archives/edgar/data/1807120/000090266425003881/xslSCHEDULE_13G_X01/primary_doc.xml
0 · Reply
Drugtrade
Drugtrade Aug. 26 at 3:48 PM
$DSGN 200 shares to start right here, fund accumulation may drive price up ahead of data catalyst. $25 target
0 · Reply
HyperbolicCapital
HyperbolicCapital Aug. 23 at 11:18 AM
$DSGN Design Therapeutics Inc is a clinical stage genetic medicine company with early development
0 · Reply
d_risk
d_risk Aug. 8 at 12:49 PM
$DSGN - Design Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors DSGN’s updated 10-Q risk factors highlight heightened clinical trial and regulatory hurdles, new anti-takeover provisions, expanded litigation and geopolitical risks, and removal of environmental and insider sale concerns, while core IP and analyst coverage risks remain unchanged. #Biotechnology #GeopoliticalRisk #LitigationRisk #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/DSGN/10-Q/2025-08-07
0 · Reply
Drugtrade
Drugtrade Jun. 6 at 6:15 PM
$DSGN favorable cash to debt ratio, no position yet.. watch for now and try to buy low
1 · Reply
G101SPM
G101SPM Jun. 4 at 11:12 AM
$DSGN Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
0 · Reply
PenkeTrading
PenkeTrading May. 31 at 11:51 AM
I found you a Evening Star Candle Pattern on the daily chart of Design Therapeutics Inc. $DSGN #Design #EveningStar #NASDAQ
0 · Reply
Armonica423
Armonica423 May. 10 at 6:38 PM
$DSGN Big exposure for CYDY at 3 oncology conferences this coming week, do your dd research
0 · Reply
Vistrix
Vistrix May. 2 at 9:30 AM
$DSGN Is my chart glitching? DSGN is at $7.48 pre market? https://finance.yahoo.com/quote/DSGN/?guccounter=1
0 · Reply
Vistrix
Vistrix May. 2 at 8:23 AM
$DSGN Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy. https://www.biospace.com/press-releases/design-therapeutics-announces-favorable-phase-1-data-for-dt-168-supporting-advancement-into-phase-2-biomarker-trial-for-patients-with-fuchs-endothelial-corneal-dystrophy
0 · Reply
MadHatterTrades74
MadHatterTrades74 Apr. 7 at 7:29 PM
$LXEO This is 1 of 4 Fredrich’s Axtasia stocks. the others being $DSGN $VYGR & $LRMR The reason for the drop today is included in the news that no real catalyst will be avail until late 2026 early 2027
1 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 26 at 7:08 PM
$DSGN Digging deep into DSGN's GeneTAC platform. Pipeline looks promising for rare genetic disorders. FA and FECD trials could be game changers. Watching closely for proof-of-concept data. Might start a small position if Phase 1 results look clean. Biotech is wild but this feels different. R&D spend looks strategic. Potential breakout incoming. great article: https://beyondspx.com/article/design-therapeutics-dsgn-a-pioneering-biotech-tackling-genetic-disorders-with-innovative-genetac-r-platform
0 · Reply
DonCorleone77
DonCorleone77 Mar. 10 at 11:58 AM
$DSGN Design Therapeutics sees cash runway into 2029 Cash, cash equivalents and marketable securities were $245.5M as of December 31, 2024, which the company expects to fund its planned operating expenses into 2029.
0 · Reply
DonCorleone77
DonCorleone77 Mar. 10 at 11:58 AM
$DSGN Design Therapeutics provides corporate highlights, anticipated milestones Friedreich Ataxia: Design has initiated dosing in a Phase 1 clinical trial in healthy volunteers in Australia to evaluate the safety and pharmacokinetics of single ascending doses of DT-216P2 via multiple routes of administration. A Phase 1/2 multiple ascending dose clinical trial to assess safety, PK and pharmacodynamics in FA patients is anticipated to begin in mid-2025. Data based on twelve weeks of DT-216P2 dosing in patients is anticipated in 2026. Fuchs Endothelial Corneal Dystrophy: Design has completed dosing in a Phase 1 MAD clinical trial of DT-168 in healthy volunteers and expects to report data in the first half of 2025. The company achieved its enrollment goal for the observational study by recruiting and completing baseline assessments on approximately 250 FECD patients. Based on the baseline characteristics data, Design has chosen approximately 100 patients for future follow-up visits. Pipeline programs: Design continues to advance preclinical work toward the selection of a development candidate for myotonic dystrophy type-1 later in 2025. Preclinical characterization of several candidate molecules also continues in Huntington's disease.
0 · Reply